High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Fibroblast activation protein α (FAP) plays an important role in tissue remodeling and helps tumor cells invade surrounding tissue. We sought to investigate FAP as a prognostic molecular marker in colorectal cancer (CRC) using immunohistochemical and transcriptomic data. FAP expression and clinicopathologic information were obtained from The Cancer Genome Atlas dataset. FAP association with tissue cellular heterogeneity landscape was explored using xCell method. FAP protein expression was evaluated in a cohort of 92 CRCs and 19 non-tumoral tissue. FAP was found upregulated in tumors both at the mRNA and protein levels and its expression was associated with advanced stages, poor survival and consensus molecular subtype 4. FAP expression was associated with angiogenesis and collagen-degradation. We observed an enrichment in immune-cell process-related genes associated with FAP overexpression. CRCs with high-FAP expression display an inflamed phenotype enriched for macrophages and monocytes. Those tumors showed enrichment for Treg populations and depletion of Th1 and natural killer T cells, pointing to an immunosuppressive environment. CRCs with high levels of stromal FAP are associated with aggressive disease progression and survival. Our results suggest other roles of FAP in tumor progression such as modulation of angiogenesis and immunoregulation in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 2×
“Indeed, the CMS1 subtype displays upregulation of proteins involved in immune response pathways (40).”
BackgroundxCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397 · cited 1×
“Cell type enrichment analysis was performed with FPKM gene expression data using xCell gene signatures-based method for cell types (38).”
MethodA pathology atlas of the human cancer transcriptome
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017) · Science · doi:10.1126/science.aan2507 · Cited by 3,371
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · cited 1×
“(63) showed that CAF with high expression of FAP was associated with increased CD25FOXP3 T lymphocytes via the modulation of B7H3, DPP4, and CD73.”
BackgroundYang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., & He, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2973 · Cited by 748
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
Chun, E., Lavoie, S., Michaud, M., Gallini, C. A., Kim, J., Soucy, G., Odze, R., Glickman, J. N., & Garrett, W. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.024 · Cited by 402 · cited 1×
“CCL2, a member of the C-C chemokine family, regulates the recruitment of myeloid cells, mostly macrophages and monocytes (60), into inflamed sites to promote tumor growth (61, 62).”
BackgroundMesker, W. E., Junggeburt, J. M. C., Szuhai, K., de Heer, P., Morreau, H., Tanke, H. J., & Tollenaar, R. A. E. M. (2007) · Analytical Cellular Pathology · doi:10.1155/2007/175276 · Cited by 354
Fearon, D. T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0002 · Cited by 288
Sandberg, T. P., Stuart, M. P. M. E., Oosting, J., Tollenaar, R. A. E. M., Sier, C. F. M., & Mesker, W. E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5462-2 · Cited by 135 · cited 1×
“(56), suggesting a role in tissue invasion and metastasis.”
Background
Cited by
YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis
Gao, R., Kalathur, R. K. R., Coto‐Llerena, M., Ercan, C., Buechel, D., Shuang, S., Piscuoglio, S., Dill, M. T., Camargo, F. D., Christofori, G., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114351 · Cited by 484
Self-citationChivu-Economescu, M., Necula, L. G., Matei, L., Dragu, D., Bleotu, C., Sorop, A., Herlea, V., Dima, S., Popescu, I., & Diaconu, C. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063214 · Cited by 42
Strating, E., Wassenaar, E., Verhagen, M., Rauwerdink, P., van Schelven, S., de Hingh, I., Rinkes, I. B., Boerma, D., Witkamp, A., Lacle, M., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01748-z · Cited by 36
“Prior work had already shown that FAP expression in CRC is associated with poor prognosis [35–37] and that FAP is highly expressed in CMS4 [38].”
BackgroundCancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers
Shah, R., Johnson, K. A., Lippert, A. E. L., Kraus, S. G., Emmerich, P. B., Pasch, C. A., Zhang, W., Matkowskyj, K. A., LeBeau, A. M., & Deming, D. A. (2024) · Cancers · doi:10.3390/cancers16183158 · Cited by 18
Metadata
- Authors
- Coto-Llerena, M., Ercan, C., Kancherla, V., Taha-Mehlitz, S., Eppenberger-Castori, S., Soysal, S. D., Ng, C. K. Y., Bolli, M., von Flüe, M., Nicolas, G. P., Terracciano, L. M., Fani, M., & Piscuoglio, S.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-08
- Volume
- 10
- Pages
- 979-979
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3041498334
- Cited by
- 99
- References
- 11
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.